Coming back to: Semaglutide in people without diabetes: what the evidence base looks like

On the subject in the title: Semaglutide in people without diabetes: what the evidence base looks like Working notes rather than a conclusion.

Two things I would like separated before anyone answers on Semaglutide in people without diabetes, because they get bundled and then argued about as one thing.

The first is descriptive: what has actually been observed, by whom, and how. The second is causal: why. I am asking about the first only.

On post #8 — agreed on the reasoning, with one qualification.

Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.

The honest answer is that it depends, and here is what it depends on.

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

Flagging that the sources on this are thinner than the confidence in the thread suggests.

Cardiovascular data in people without diabetes is the specific contribution of SELECT, and it is worth being precise that the enrolled population had established cardiovascular disease. That is not the same as the general population and the result should not be quoted as though it were.

Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.

Worth reading the earlier posts in this thread before acting on mine.

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

That has held every time I have looked, which is not the same as always.

Nausea is dose-related and adaptation-related, and both are true at once. The pattern most people describe is a return of symptoms at each escalation followed by adaptation, rather than a single course of adaptation at the start.

Filing this under things that are true until someone shows me otherwise.